Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 20/20 | 0.86 |
| ▸ | F10 | P00742 | 5/20 | 0.86 |
| ▸ | PLG | P00747 | 4/20 | 0.86 |
| ▸ | PLAT | P00750 | 4/20 | 0.86 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.85 |
| ▸ | F9 | P00740 | 2/20 | 0.85 |
| ▸ | PROC | P04070 | 2/20 | 0.78 |
| ▸ | F2 | P00734 | 1/20 | 0.71 |
| ▸ | PLAU | P00749 | 1/20 | 0.71 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.71 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.71 |
| ▸ | F7 | P08709 | 1/20 | 0.71 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10263763 | 0.96 | F11 (0.89) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478346 | 0.96 | F11 (0.89) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478345 | 0.96 | F11 (0.89) | F11F10PLGPLATKLKB1 | |
| SCHEMBL10263989 | 0.94 | F11 (0.87) | F11F10PLGPLATKLKB1 | |
| SCHEMBL940140 | 0.94 | F11 (0.87) | F11F10PLGPLATKLKB1 | |
| SCHEMBL480377 | 0.94 | F11 (0.87) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478632 | 0.93 | F11 (0.84) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478631 | 0.93 | F11 (0.84) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478239 | 0.93 | F11 (0.84) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478240 | 0.93 | F11 (0.84) | F11F10PLGPLATKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102026996-A | Pyridazine derivatives as factor XIA inhibitors | BRISTOL MYERS SQUIBB CO | 2011-04-20 | — | — | CN | disclosed |